Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

An Acute Gvhd Classification Based on the Dynamic of Gvhd Skin Involvement from Its Appearance to Start of Systemic Treatment

Giuseppe Milone, Salvatore Leotta, Sara Frazzetto, Giulia Giuffrida, Giulio Antonio Milone, Sebastiano Fiore, Benedetta Esposito, Giordana Brunetti, Andrea Spadaro, Maria Grazia Camuglia, Alessandra Cupri

Blood (2023) 142 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2023-172724

Published: 2023

Journal Articles

Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

Salvatore Leotta, Andrea Duminuco, Antonino Mulè, Stefania Tringali, Elisa Mauro, Calogero Vetro, Cinzia Maugeri, Marina Parisi, Bruno Garibaldi, Nicola Di Renzo, Claudia Romano, Domenico Pastore, Massimo Gentile, Ernesto Vigna, Carmine Selleri, Giuseppe Milone, Uros Markovic

Blood (2022) 140 (Supplement 1): 11854–11855.

https://doi.org/10.1182/blood-2022-166546

Published: 2022

Journal Articles

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

Uros Markovic, Andrea Duminuco, Nunziatina Laura Parrinello, Luca Lo Nigro, Elisa Mauro, Calogero Vetro, Marina Parisi, Cinzia Maugeri, Giuseppe Milone, Alessandra Romano, Francesco Di Raimondo, Salvatore Leotta

Blood (2022) 140 (Supplement 1): 11847–11848.

https://doi.org/10.1182/blood-2022-170177

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

Utility of Procalcitonin and Interleukin-6 As Severe Infection Biomarkers in Adulthematological and Oncological Patients. Real-Life Single Center Prospective Observational Study

Blood (2022) 140 (Supplement 1): 12931–12932.

https://doi.org/10.1182/blood-2022-166369

Published: 2022

Journal Articles

Sars-Cov-2 Vaccination Response Monitoring in Lymphoma and Multiple Myeloma Patients Following Standard Versus High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Uros Markovic, Giulio Antonio Milone, Daniela Carco, Valeria Iachelli, Nunziatina Laura Parrinello, Paola Scire, Gabriella Amato, Federica Galbo, Giuseppe Milone, Emanuele Martorana, Gaetano Moschetti

Blood (2022) 140 (Supplement 1): 7705–7706.

https://doi.org/10.1182/blood-2022-166703

Published: 2022

Journal Articles

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 7667–7669.

https://doi.org/10.1182/blood-2022-162472

Published: 2022

Journal Articles

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Blood (2022) 140 (Supplement 1): 10622–10623.

https://doi.org/10.1182/blood-2022-162298

Published: 2022

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136316

Published: 2020

Journal Articles

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Alessandra Cupri, MD, Salvatore Leotta, MD, Uros Markovic, MD, Maria Grazia Camuglia, PhD, Giulio Antonio Milone, MD, Angelo Curto Pelle, MD, Valerio Leotta, MD, Mary Ann Di Giorgio, MD, Anna Bulla, MD, Di Marco Anna Lia, PhD, Gaetano Moschetti, MD, Giuseppe Milone, MD PhD

Blood (2019) 134 (Supplement_1): 3271.

https://doi.org/10.1182/blood-2019-127120

Published: 2019

Journal Articles

Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens

Nicola Di Renzo, MD, Maurizio Musso, MD, Rosanna Scimè, MD, Giuseppe Milone, MD PhD, Tommasina Perrone, MD, Clara De Risi, MD, Domenico Pastore, MD PhD, Attilio Guarini, MD, Andrea Mengarelli, MD, Fabio Benedetti, MD, Patrizio Mazza, MD, Vera Capria, MD, Patrizia Chiusolo, Luca Cupelli, MD, Vincenzo Federico, MD, Valentina Bozzoli, PhD MD, Anna Rita Messa, Giorgina Specchia, MD

Blood (2019) 134 (Supplement_1): 1974.

https://doi.org/10.1182/blood-2019-125071

Published: 2019

Journal Articles

FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT

Roni Shouval, MD PhD, Myriam Labopin, MD, David Bomze, MSc, Gabriela M Baerlocher, Robin Foà, MD, Didier Blaise, Mathias Haenel, MD, Edouard Forcade, MD, Anne Huynh, MD, Riccardo Saccardi, MD, Giuseppe Milone, MDPhD, Tsila Zuckerman, MD, Péter Reményi, MD, Jordi Esteve, MD PhD, Norbert Claude Gorin, MDPhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 609.

https://doi.org/10.1182/blood-2018-99-111614

Published: 2018

Journal Articles

ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience

Blood (2018) 132 (Supplement 1): 3381.

https://doi.org/10.1182/blood-2018-99-110252

Published: 2018

Journal Articles

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Blood (2018) 132 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2018-99-114486

Published: 2018

Journal Articles

High Level of IL-2-Receptor and of TIM-3 in Plasma at Day +18 after Allogeneic Transplantation Can Identify Early Patients at Risk for Treatment Related Mortality

Giuseppe Milone, MDPhD, Viviana Frontini, Alessandra Cupri, Salvatore Leotta, Annalia DiMarco, Carla Consoli, Luca Scalise, Giuseppe Sapienza, Gaetano Moschetti, Giuseppe Avola, Andrea Spadaro, AnnaElisa Marchese, PhD

Blood (2017) 130 (Supplement 1): 4497.

https://doi.org/10.1182/blood.V130.Suppl_1.4497.4497

Published: 2017

Journal Articles

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Giuseppe Milone, MDPhD, Annalia DiMarco, Giuseppe Sapienza, Salvatore Leotta, Luca Scalise, Carla Consoli, Maria Cristina Pirosa, Alessandra Cupri, Gaetano Moschetti, Maria Grazia Camuglia, Maria Sciacca, AnnaElisa Marchese, PhD

Blood (2017) 130 (Supplement 1): 5098.

https://doi.org/10.1182/blood.V130.Suppl_1.5098.5098

Published: 2017

Journal Articles

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Blood (2017) 130 (Supplement 1): 519.

https://doi.org/10.1182/blood.V130.Suppl_1.519.519

Published: 2017

Journal Articles

Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS)

Anna Dodero, Francesca Patriarca, Giuseppe Milone, MD, Barbara Sarina, MD, Rosalba Miceli, Anna Paola Iori, Francesco Barretta, Elisabetta Terruzzi, MD, Alberto Mussetti, MD, Massimo Pini, MD, Alberto Bosi, Alida Dominietto, MD, Nicola Cascavilla, MD, Francesco Onida, MD, Franco Narni, Lucia Farina, MD PhD, Alessandro Rambaldi, MD, Paolo Corradini

Blood (2016) 128 (22): 3473.

https://doi.org/10.1182/blood.V128.22.3473.3473

Published: 2016

NARROW

An Acute Gvhd Classification Based on the Dynamic of Gvhd Skin Involvement from Its Appearance to Start of Systemic Treatment

Minimal Residual Disease Negativity after Blinatumomab Is Predictive of Survival in B-Cell Acute Lymphoblastic Leukemia: Data from a Real-Life Study

T-Cell Lymphocyte Kinetics As a Predictive Biomarker of Blinatumomab MRD Response in ALL-B Patients: A Single-Center Prospective Study

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Utility of Procalcitonin and Interleukin-6 As Severe Infection Biomarkers in Adulthematological and Oncological Patients. Real-Life Single Center Prospective Observational Study

Sars-Cov-2 Vaccination Response Monitoring in Lymphoma and Multiple Myeloma Patients Following Standard Versus High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877)

Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT

ANTI-CMV Immunoglobulins in Association with ANTI-CMV Drugs in Patients with Hematological Malignancies Submitted to Allogeneic STEM CELL Transplantation: A MULTI-Center Retrospective Experience

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

High Level of IL-2-Receptor and of TIM-3 in Plasma at Day +18 after Allogeneic Transplantation Can Identify Early Patients at Risk for Treatment Related Mortality

Red Cell Distribution Width (RDW) As Prognostic Factor in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Transplantation

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Final Results of a Multicenter Prospective Phase II Trial of Allogeneic Transplantation for Relapsed/Refractory CD20+ B-Cell Lymphomas: Effect of Rituximab on Graft-Versus-Host Disease-Free/Relapse-Free Survival (GRFS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only